Public Health Impact Assessment of RSVPreF3 OA Adjuvanted Vaccine on Respiratory Syncytia Virus in Taiwan, Hong Kong, and Singapore
Author(s)
Yu-Fan Ho, MPH1, Ellis Hon, PhD2, Ivan Hung, PhD3, Helen May Lin Oh, PhD4, Limin Wijaya, PhD4, Pin-Kuei Fu, PhD5, Yhu-Chering Huang, PhD6, Beverly Giam, PhD7, Corina Poh, MSc7, Man-Ying Ko, PhD8, Hanna Lee, PhD9, Aruni Seneviratna, PhD7.
1Real World Evidence & Health Outcomes, GlaxoSmithKline, Singapore, Singapore, 2Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China, Hong Kong, Hong Kong, 3The University of Hong Kong, Hong Kong, Hong Kong, 4SingHealth, Singapore, Singapore, 5Taichung Veterans General Hospital · Department of Medical Research, Taichung, Taiwan, 6Chang Gung Memorial Hospital, Taipei, Taiwan, 7GlaxoSmithKline, Singapore, Singapore, 8GlaxoSmithKline, Hong Kong, Hong Kong, 9GlaxoSmithKline, Taipei, Taiwan.
1Real World Evidence & Health Outcomes, GlaxoSmithKline, Singapore, Singapore, 2Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China, Hong Kong, Hong Kong, 3The University of Hong Kong, Hong Kong, Hong Kong, 4SingHealth, Singapore, Singapore, 5Taichung Veterans General Hospital · Department of Medical Research, Taichung, Taiwan, 6Chang Gung Memorial Hospital, Taipei, Taiwan, 7GlaxoSmithKline, Singapore, Singapore, 8GlaxoSmithKline, Hong Kong, Hong Kong, 9GlaxoSmithKline, Taipei, Taiwan.
OBJECTIVES: Respiratory syncytial virus (RSV) is a contagious pathogen that causes acute respiratory illness (ARI) in individuals of all ages and represents a significant health burden among older adults (OAs) aged ≥60 years in Asia. In this population, RSV can lead to lower respiratory tract disease (LRTD) and complications such as pneumonia, exacerbations of chronic respiratory disease, cardiovascular complications, ICU admissions, and death.This study aims to evaluate the potential public health impact (PHI) of the GSK RSVPreF3 OA adjuvanted vaccine, the first approved preventive intervention for RSV for OAs aged ≥60 in Hong Kong, Singapore, and Taiwan.
METHODS: A static multi-cohort Markov model with monthly cycles was developed to assess the impact of RSVPreF3 OA adjuvanted vaccine on OAs ≥60 years across selected countries. The model compares a single dose of RSV vaccine to no-vaccination over a five-year time horizon, estimating the PHI of RSV vaccination in preventing RSV disease.Input data are based on the best available data from published literature, while vaccine efficacy and waning rates were informed by the AReSVi-006 phase 3 clinical trial.
RESULTS: Over the five-year horizon, the base case analysis estimated that compared with no vaccination, RSVPreF3 OA adjuvanted vaccine could reduce 9,168 to 108,021 cases of LRTD, 1,934 to 10,979 hospitalizations, and 136 to 767 deaths. The Number Needed to Vaccinate (NNV) ranges from 28 to 30 for LRTD, 142 to 297 for hospitalizations, and 2,023 to 4,252 for deaths.
CONCLUSIONS: Results indicate a significant preventive effect of the RSVPreF3 OA adjuvanted vaccination on RSV ARI cases among OAs aged 60 and older in Taiwan, Hong Kong and Singapore, resulting in considerable public health benefits. While ongoing studies may refine precision, extensive sensitivity analysis suggest that preventing RSV is essential for safeguarding the health and well-being of the OA population in Asia.
Funding: GSK
METHODS: A static multi-cohort Markov model with monthly cycles was developed to assess the impact of RSVPreF3 OA adjuvanted vaccine on OAs ≥60 years across selected countries. The model compares a single dose of RSV vaccine to no-vaccination over a five-year time horizon, estimating the PHI of RSV vaccination in preventing RSV disease.Input data are based on the best available data from published literature, while vaccine efficacy and waning rates were informed by the AReSVi-006 phase 3 clinical trial.
RESULTS: Over the five-year horizon, the base case analysis estimated that compared with no vaccination, RSVPreF3 OA adjuvanted vaccine could reduce 9,168 to 108,021 cases of LRTD, 1,934 to 10,979 hospitalizations, and 136 to 767 deaths. The Number Needed to Vaccinate (NNV) ranges from 28 to 30 for LRTD, 142 to 297 for hospitalizations, and 2,023 to 4,252 for deaths.
CONCLUSIONS: Results indicate a significant preventive effect of the RSVPreF3 OA adjuvanted vaccination on RSV ARI cases among OAs aged 60 and older in Taiwan, Hong Kong and Singapore, resulting in considerable public health benefits. While ongoing studies may refine precision, extensive sensitivity analysis suggest that preventing RSV is essential for safeguarding the health and well-being of the OA population in Asia.
Funding: GSK
Conference/Value in Health Info
2025-09, ISPOR Real-World Evidence Summit 2025, Tokyo, Japan
Value in Health Regional, Volume 49S (September 2025)
Code
RWD298
Topic Subcategory
Health & Insurance Records Systems
Disease
STA: Vaccines